...
首页> 外文期刊>Journal of Alzheimer's disease: JAD >Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers
【24h】

Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers

机译:淀粉样PET成像在非典型性痴呆鉴别诊断中的临床应用及其对护理人员的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Recent studies have supported a role for amyloid positron emission tomography (PET) imaging in distinguishing Alzheimer's disease (AD) pathology from other pathological protein accumulations leading to dementia. We investigated the clinical utility of amyloid PET in the differential diagnosis of atypical dementia cases and its impact on caregivers. Using the amyloid tracer 18F-NAV4694, we prospectively scanned 28 patients (mean age 59.3 y, s.d. 5.8; mean MMSE 21.4, s.d. 6.0) with an atypical dementia syndrome. Following a comprehensive diagnostic workup (i.e., history taking, neurological examination, blood tests, neuropsychological evaluation, MRI, and FDG-PET), no certain diagnosis could be arrived at. Amyloid PET was then conducted and classified as positive or negative. Attending physicians were asked to evaluate whether this result led to a change in diagnosis or altered management. They also reported their degree of confidence in the diagnosis. Caregivers were met after disclosure of amyloid PET results and completed a questionnaire/interview to assess the impact of the scan. Our cohort was evenly divided between positive (14/28) and negative (14/28) 18F-NAV4694 cases. Amyloid PET resulted in a diagnostic change in 9/28 cases (32.1%: 17.8% changed from AD to non-AD, 14.3% from non-AD to AD). There was a 44% increase in diagnostic confidence. Altered management occurred in 71.4% (20/28) of cases. Knowledge of amyloid status improved caregivers' outcomes in all domains (anxiety, depression, disease perception, future anticipation, and quality of life). This study suggests a useful additive role for amyloid PET in atypical cases with an unclear diagnosis beyond the extensive workup of a tertiary memory clinic. Amyloid PET increased diagnostic confidence and led to clinically significant alterations in management. The information gained from that test was well received by caregivers and encouraged spending quality time with their loved ones.
机译:最近的研究支持淀粉样蛋白正电子发射断层扫描(PET)成像在区分阿尔茨海默氏病(AD)病理学与导致痴呆的其他病理性蛋白积累中的作用。我们调查了淀粉样蛋白PET在非典型痴呆病例的鉴别诊断中的临床效用及其对护理人员的影响。我们使用淀粉样蛋白示踪剂18F-NAV4694,对28例非典型痴呆综合征患者(平均年龄59.3岁,s.d. 5.8;平均MMSE 21.4,s.d。6.0)进行了前瞻性扫描。经过全面的诊断检查(即历史记录,神经系统检查,血液检查,神经心理学评估,MRI和FDG-PET),无法确定诊断。然后进行淀粉样蛋白PET并分类为阳性或阴性。要求主治医师评估该结果是否导致诊断改变或管理改变。他们还报告了他们对诊断的信心程度。淀粉样蛋白PET结果公开后,护理人员得到了满足,并完成了问卷/访谈以评估扫描的影响。我们的队列在阳性(14/28)和阴性(14/28)18F-NAV4694病例之间平均分配。淀粉样蛋白PET导致9/28例的诊断改变(32.1%:从AD变为非AD,占17.3%,从非AD变为AD,占14.3%)。诊断信心增加了44%。 71.4%(20/28)的病例发生了管理变更。对淀粉样状态的了解可以改善护理人员在所有方面的结果(焦虑,抑郁,疾病感知,未来预期和生活质量)。这项研究表明,淀粉样蛋白PET在非典型病例中具有有用的累加作用,除了三级记忆诊所的广泛检查外,还没有明确的诊断。淀粉样蛋白PET增加了诊断的信心,并导致了临床上管理上的重大改变。从该测试中获得的信息受到护理人员的好评,并鼓励他们与亲人共度美好时光。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号